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Abstract
Background: Adherence is a crucial point for the successful treatment of a hepatitis-C virus infection. Studies have
shown that especially adherence to ribavirin is important.
The objective of this systematic review was to identify factors that influence adherence in hepatitis-C infected
patients taking regimes that containing ribavirin.
Methods: A systematic literature search was performed in Medline and Embase in March 2014 without limits for
publication date. Titles and abstracts and in case of relevance, full-texts were screened according to predefined
inclusion criteria. The risk of bias was assessed. Both process steps were carried out independently by two reviewers.
Relevant data on study characteristics and results were extracted in standardized tables by one reviewer and checked
by a second. Data were synthesized in a narrative way using a standardized procedure.
Results: Nine relevant studies were identified. The number of analyzed patients ranged between 12 and 5706 patients.
The study quality was moderate. Especially the risk of bias regarding the measurement of influencing factors was mostly
unclear.
“Psychiatric disorders” (N = 5) and having to take “higher doses of ribavirin” (N = 3) showed a negative influence
on adherence. In contrast, a “HIV co-infection” (N = 2) and the “hemoglobin level” (N = 2) were associated with a
positive influence on adherence. Furthermore, there is the tendency that male patients are more adherent than
female patients (N = 6). “Alcohol consumption” (N = 2), “education”, “employment status”, “ethnic group“,”hepatitis-C virus
RNA” (N = 4), “genotype” (N = 5), “metavir activity” (N = 1) and “weight” (N = 3) showed mostly no effect on adherence.
Although, some studies showed statistically significant results for “age”, “drug use” , “genotype”, “medication dose
interferon“, and “treatment experience” the effect is unclear because effect directions were partly conflicting.
The other factors were heterogeneous regarding the effect direction and/or statistical significance.
Conclusion: There are some factors that seem to show an influence on adherence. However, due to the heterogeneity
(e.g. patient characteristics, regimes, settings, countries) no general conclusions can be made. The results should rather
be considered as indications for factors that can have an influence on adherence in hepatitis-C infected patients taking
regimes that containing ribavirin.
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Background
In developed countries the prevalence of hepatitis-C virus
infections ranges between 1.3 and 2.7% [1]. About 18.5% of
hepatitis-C virus infected patients develop cirrhosis and
1.3% a hepatocellular carcinoma [2]. Prior research has
shown that adherence, as “the extent to which a patient acts
in accordance with the prescribed interval and dose of a
dosing regimen” is a crucial point for successful treatment
of a hepatitis-C virus infection [3-5]. Although new drugs
for the treatment of Hepatitis-C entered the market, ribavi-
rin is still important to reach sustained virologic response
(SVR) [6]. Studies have shown that reducing the dose of ri-
bavirin from ≥80% to ≤60% resulted in a decline of SVR
form 21% to 11% (p ≤ 0.05). In contrast, reduced peg-
interferon use was not associated with a decline in SVR [7].
Furthermore, research has shown that in the combination
therapy for hepatitis-C with interferon and ribavirin, adher-
ence is lower for ribavirin than for interferon [8].
Several factors (e.g. patient characteristics, treatment
characteristics, disease characteristics, setting) exist that can
potentially influence patient adherence. The factors can be
grouped in the following five dimensions: social and eco-
nomic, health care system, health condition, therapy and
patient [9].
Systematic reviews for various indications have identi-
fied factors that can influence patient adherence [10-12].
For example, Bowry et al. [10] found poor knowledge,
negative perceptions about medication, side effects and
high medication costs to be predictive for non-adherence
in patients taking cardiovascular medications. Jackson et al.
[11] could not find a clear effect for any demographic, clin-
ical, or treatment factors in patients with bowel disease.
Verbrugghe et al. showed that younger age and side effects
were the two predominate factors for adherence in pa-
tients taking oral anti-cancer agents [12]. But to the best
of our knowledge there is no systematic review that in-
vestigates adherence influencing factors in hepatitis-C
virus infected patients The objective of this systematic
review was to identify factors that influence adherence




This systematic review was prepared according to the stan-
dards of the recommendations for systematic reviews of
prognostic factors and reported according to MOOSE
[13,14]. A systematic literature search was performed in
MEDLINE (via Pubmed) and Embase (via Embase) (TM).
The search strategy combined various terms and medical
subject headings related to adherence, hepatitis-C and
ribavirin (the full search strategies for each database are
available in Additional file 1). The search was performed
on March 25th 2013. Study type, publication date and
language were not limited in the electronic search strategy
to maximize sensitivity.
Study selection
To be eligible for this review the studies had to meet the
following inclusion criteria:
1. Patients: Adult patients with hepatitis-C virus
infection
2. Exposure: Potential adherence influencing factor/s
(exposure [factor] is not controlled by the
investigator, e.g. different dosages or therapies)
3. Medication: Regimes containing ribavirin
4. Outcome: Quantitative patient implementation
adherence [15] measure (not persistence, not
exclusively intentional-adherence measures)
5. Region: Study conducted in WHO- mortality
Stratum A (very low child mortality and low adult
mortality) [16]
6. Publication language: English or German
No exclusion criteria were applied.
Two reviewers independently performed the study selec-
tion according to the inclusion criteria in a two-step pro-
cedure (DP; SA, TM). Firstly, the titles and abstracts of all
hits in the electronic databases were screened. Secondly,
the full-texts of all potentially relevant articles were ob-
tained and screened. Any differences between the reviewers
were discussed until consensus was reached. In addition,
the reference lists of all included publications were hand-
searched and a Google Scholar search was performed to
identify grey literature (TM). The authors were contacted
in case of any missing information regarding the inclusion
criteria (TM).
According to established recommendations a differen-
tiation between initiation, implementation and discon-
tinuation adherence should be made [15]. In clinical
practice initiation and discontinuation of a medication
regimen can be easily assessed. In contrast, implementa-
tion adherence is often not obvious. Furthermore, re-
search indicates that the reasons for discontinuation and
implementation adherence can differ [17]. Thus, it was
decided to focus on implementation adherence. Non-
adherence can be intentional (e.g. conscious decision
not to take) or non-intentional (e.g. forgetting). Further-
more, it has been shown that non-adherence is mostly
non-intentional and that there are different influencing
factors [18,19]. Therefore, we excluded studies that only
measured intentional non-adherence like surveys that
gathered reasons for non-adherence stated by patients.
Assessment of risk of bias
The risk of bias of included studies was assessed using the
methodology checklist for prognostic studies provided by
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the National Institute for Health and Care Excellence
(NICE) (evaluation questions for the instruments are
available in Additional file 2) [20]. The study popula-
tion was considered representative, if there were no
specific inclusion criteria (e.g. psychiatric disorders)
i.e. if the population was representative for the general
hepatitis-C infected population in western countries.
Confounding was rated appropriate if the potentially
relevant factors were incorporated in the analysis. The
risk of bias assessment was performed independently
by two reviewers (TM, DP). Disagreements were re-
solved in a discussion or by involving a third person.
Data extraction and synthesis
The data were extracted in pre-designed standardized ta-
bles. For each study the number of analyzed patients, the
study inclusion criteria (demographic, socioeconomic, dis-
ease related, medication related), the country the study took
place, the used adherence measure and mathematical oper-
ationalization, and the medications to which the adherence
measure (ribavirin or ribavirin and interferon) refers to
were extracted. With respect to the results, the influencing
factor and the effect on adherence (effect direction or com-
pared categories; effect size and measure) and the statistical
significance (95%-CI or p-value) were extracted. All data in
the tables on the influence refers to an increase of the re-
spective factor, independent from whether the factor is
positive (e.g. educational level) or negative (adverse events).
Higher risk ratios (RR) and odds ratios (OR) mean lower
adherence in the reference group. e.g. in a comparison of
higher versus lower age, a higher OR indicates a higher ad-
herence in the higher aged population. In case the studies
used univariate as well as multivariate analysis methods,
only the results of the multivariate analysis were extracted.
Data extraction were performed by one reviewer (TM) and
verified by a second (DP). If effect sizes and statistical sig-
nificance were not reported in the publications, the OR
with confidence intervals were calculated by the authors
(Microsoft Excel 2010) using the double data entry method,
provided that there were sufficient data (TM, DP).
A quantitative data synthesis using a meta-analysis was
planned a priori but was not performed to avoid misleading
results due to heterogeneity regarding the included pa-
tients, the adherence measurements and definitions/opera-
tionalization, the measurement of influencing factors,
and the statistical analysis methods (e.g. adjustments,
categorizations). Furthermore, in most studies there
was a significant lack of reporting especially regarding
values for not statistically significant results to allow a
recalculation of data.
For all factors that were analyzed in at least two stud-
ies a summary estimation of the effect direction and the
effect size was made. Two reviewers rated the evidence
for an effect, considering the consistency of the effect
direction (within and between studies), the effect size,
the statistical significance, the sample size and the risk
of bias of included studies that analyzed the respective
factor (TM, DP). Discrepant ratings were discussed until
consensus.
A p-level of < 0.05 was considered statistically
significant.
Results
The electronic literature search resulted in 413 hits.
Thirty nine of the titles and abstracts seemed potentially
relevant and full-text versions of the publications were
screened. Nine studies met all inclusion criteria and
were included in the systematic review [4,8,21-27]. The
process of study selection and the reasons for exclusion
are illustrated in the flowchart (see Figure 1).
The risk of bias was moderate. In particular the repre-
sentativeness of the study sample and the consideration
of confounders were insufficient in most studies. The
studies that applied an adjusted analysis considered the
potentially relevant confounders, i.e. the studies that
were rated with minus were unadjusted. Furthermore,
no statements on the measurement of the influencing
factors and descriptions of the patients lost-to-follow-up
could be found in many studies. The results of the risk of
bias assessment for each study are presented in Table 1.
The number of analyzed patients ranged between 12
and 5706 patients. In two studies the study population
was highly specified. Giannelli et al. [21], included only
liver transplanted patients and Lo Re exclusively US Vet-
erans [4]. Except the study by Marcellin et al. [8], all
studies were performed in hospitals and medical centers.
To measure adherence either pill counts or self-reports
were applied. In two studies the analysis was based on the
adherence to ribavirin [4,22]. The remaining studies ana-
lyzed the influencing factors on the basis of combined mea-
sures for ribavirin and interferon. In two studies adherence
was operationalized as the mean proportion of doses taken
[4,23]. In all other studies adherence was operationalized
as the proportion of patients taking a certain number of
doses (adherent patients). Besides two exceptions [8,27],
the threshold for classifying patients as adherent was set to
80%. The characteristics of studies are presented in Table 2.
The measured adherence rates in the studies using the
80% threshold (seven out of nine studies) ranged from
0.38 to 0.94.
Out of the factors that were analyzed in only one
study “anemia”, “new use of growth factors”, “new use
of thyroid medications”,, “intended treatment duration”,
“(actual) treatment duration”, “leucocyte count”, and
“treatment center size” showed a statistically significant
influence on adherence. The results of the individual
analyses for each influencing factor are presented in
Table 3.
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18 influencing factors were analyzed in more than one
study (age, alcohol consumption, depression, [illicit] drug
use, education, employment status, ethnic group, gender,
genotype, haemoglobin, hepatitis-C virus RNA, HIV co-
infection, medication dose interferon, medication dose ri-
bavirin, metavir activity, psychiatric disorder, treatment
experience, weight). The factors that were analyzed in
more than one study are presented in Table 4.
“Depression” showed a mainly negative effect on ad-
herence. Two out of four studies showed a statistically
significant effect [4,8,23,27]. However, one study showed
a conflicting effect direction [23].
Also “psychiatric disorders in general” found to have a
negative effect on adherence. All studies that analyzed
this factor showed this effect direction and one study
was statistically significant [4,8,25,27].
Higher doses of ribavirin were associated with lower
adherence. The effect direction between the studies
was consistent and one study was statistically signifi-
cant [8,21,26].
There is a strong tendency that having a “HIV co-
infection” influences adherence positively. One out of
two studies was statistically significant and showed a
large effect size [8,24].
The “hemoglobin level” showed a positive effect on
adherence. Both studies that analyzed this outcome
showed this effect direction and one was statistically
significant [24,26].
There is the tendency that male patients are more ad-
herent than female patients. Two studies were statisti-
cally significant in favor of this effect direction. But one
statistically non-significant study showed a conflicting
effect direction and three studies were statistically not
significant [8,21,24-27].
“Alcohol consumption” [8,24], “education” [8,27], “em-
ployment status” [8,27], “ethnic group“ [25,27], ”hepatitis-C
virus RNA” [8,24,26,27], “genotype”, “metavir activity” [8]
and “weight” [8,24,26], showed no statistically significant ef-
fect throughout. Although some studies showed statistically
significant results for “age”, “drug use”, “genotype”, “medi-
cation dose interferon“, and “treatment experience” the ef-
fect is unclear because effect directions were partly
conflicting i.e. some studies showed a positive effect and
some studies a negative effect on adherence.
Identified by literature search
n=413





Excluded after abstract 
screening
n=374









Figure 1 Flow-chart of study selection process.













Giannelli 2012 [21] - + + ? ? ?
Lo Re [4] - + ? + + +
Marcellin 2011 [8] + + ? + + +
Martín-Santos 2008 [22] - ? + ? - +
Rodis [23] + ? ? + - ?
Sola [24] - + ? + + +
Sylvestre [25] - + + + - +
Tanioka [26] + ? + ? + +
Wagner [27] - ? + + - +
+ = yes; − = no; ? = unclear.
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Transplanted for at least 6 months
Positive test for anti-hepatitis-C virus and
hepatitis-C virus RNA
Liver biopsy demonstrating a recurrence of
chronic hepatitis-C




Lo Re [4] Cohort
study
5706 90 days US veterans Veterans affairs medical
facilities/USA
Pill count Doses taken (ribavirin) 0.86
Hepatitis-C virus infected
Genotype 1, 2, 3, or 4
At least one prescription each for peg-
interferon and ribavirin
Viral load prior to hepatitis-C virus therapy










Chronic hepatitis-C University hospitals, non-
University hospitals and pri-
vate practice offices, hospitals/
France













146 4-24 weeks Chronic Hepatitis-C Hospitals/Spain NR Patients taking ≥80% of
doses (ribavirin)
0.89
Therapy with peg-interferon alpha-2a and
ribavirin
Substance abuse abstinence ≥ 6 months
No cognitive or language difficulties
No other liver diseases
No co-infection with hepatitis-B or HIV
No hepatocellular carcinoma
No autoimmune disorders




















Table 2 Study characteristics (Continued)
Platelet count
of >75 × 109⁄l

















157 72 weeks Chronic Hepatitis-C and hepatitis-C virus RNA
positive in plasma











Findings on liver biopsy consistent with
presence of chronic hepatitis-C , and
compensated liver disease
CD4 cell count >200 × 106/mm3 regardless
of plasma HIV RNA level or CD4 cell count
<200 × 106/mm3 wiimes;th undetectable HIV
RNA level
Neutrophil count ≥1500/mm3; platelet count
≥70,000/mm3; hemoglobin level ≥11
g/dl for women,
or ≥12 g/dl for men
No previous treatment with interferon or
ribavirin




No active drug or alcohol consumption
within the last 6 months






71 48 weeks Hepatitis-C Clinic/USA Self-report by monthly
questionnaire Pill count





Maintained on methadone for 3 months
At least 75% attendance at our weekly clinics
for a period of at least 2 months































Aminotransferase above the upper normal
limit in the 6 months before entry in to the
study
Compensated liver function with normal
levels of serum albumin, prothrombin time
and serum bilirubin
No chronic liver diseases
No injected drugs or abused alcohol within
the previous 6 months













Interferon based hepatitis-C virus treatment Medical center/USA





















This is the first review that systematically analyzes ad-
herence influencing factors in hepatitis-C infected pa-
tients taking ribavirin. There are several factors that
seem to influence adherence in hepatitis-C infected pa-
tients taking ribavirin. “Psychiatric disorders/depression”,
“higher doses ribavirin” seem to have a negative influ-
ence on adherence. In contrast “HIV co-infection” and
“hemoglobin level” seem to have a positive influence on
adherence. Furthermore, there is the tendency that male
patients are more adherent than female patients. “Alcohol
consumption”, “education”, “employment status”, “ethnic
Table 3 Influence of factors on adherence for factors that were analyzed in one study
Study Factor Effect direction or compared categories; effect size; 95%-CI or p-value
Giannelli 2012 [21]* Anemia Negative; NR; < 0.05
Lo Re [4] Methadone use Yes vs. no; OR = 0.99; 0.167
New use of growth factors Yes vs. no; OR = 1.01; 0.021
New use of thyroid medication Yes vs. no; OR = 1.02; 0.022
Schizophrenia Yes vs. no; OR = 1.00; 0.605
Marcellin 2011 [8]* Adverse events Yes vs. no; OR# = 1.09; 0.77 to 1.54
Diabetes (baseline and follow-up) NR; NR; > 0.05
Duration of infection Positive; NE; 0.601#
Fibrosis scores NR; NR; > 0.05
HCB positive Yes vs. no; OR# = 1.47; 0.62 to 3.48
Naïve for Hepatitis-C virus treatment Yes vs. no; OR = 1.32; 1.03 to 1.69
Origin of incomes Paid employment vs. others; OR# =1.12; 0.91 to 1.38
Other chronic disease (baseline) Yes vs. no; OR# = 0.91; 0.72 to 1.15
Remoteness of the center (transport time) Per min; OR = 1.00; 1.00 to 1.01
Source of Hepatitis-C virus infection Intra venous drug use vs. others; OR# = 0.99; 0.80 to 1.22
Therapeutic education (not specified) NR; NR; > 0.05
Sola [24]* Alanin-Aminotransferase NR; NR; > 0.05
Alkaline phosphatase NR; NR; > 0.05
Aspartate aminotransferase NR; NR; > 0.05
Fibrosis metavir score NR; NR; > 0.05
Leukocytes Positive; NE; 0.007#
Platelets NR; NR; > 0.05
Prothrombin time NR; NR; > 0.05
Serum albumin NR; NR; > 0.05
Serum bilirubin NR; NR; > 0.05
Sylvestre [25]*# Duration of abstinence ≥ 1 month vs. < 1 month; MD = 27%; 0.10
Psychiatric medication (baseline) NR; NR; 0.2
Psychiatric medication (during treatment) NR; NR; 0.3
Psychiatric medication (initiation during treatment) Yes vs. no; MD = −28%; 0.02
Tanioka [26] Physicians experience (years) ≥ 19 vs. < 19; RR = 1.54; 0.96 to 2.48
Platelet count (104/ml) ≥ 15 vs. < 15; RR# = 0.86; 0.57 to 1.29
Treatment center size (cases per center) ≥ 15 vs. < 15; RR = 1.65; 1.04 to 2.64
White blood cell count (ml) ≥ 5000 vs. < 5000; RR# = 1.16; 0.77 to 1.75
Wagner [27]*# Drinking problem Yes vs. no; OR = 0.63; 0.16 to 2.44
HIV RNA ≤ 400 vs. >400; OR = 1.83; 0.51 to 6.53
In a relationship Yes vs. no; OR = 0.81; 0.24 to 2.75
NE: not reported and not estimable (e.g. continuous variable); NR: not reported; OR: odds ratio; RR: relative risk; *Analysis based on combined adherence rates for
interferon and ribavirin; #univariate; wording according to publication.
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Table 4 Influence of factors on adherence for factors that were analyzed in more than one study
Factor Study Effect on adherence (effect direction or compared categories; effect
size; p-value)
Age Marcellin 2011 [8]* NR ; NR; > 0.05
Sola [24]* NR; NE; 0.01#
Sylvestre [25]*# (years) < 55 vs. ≥ 55; RR = 2.38; 1.49 to 3.80
Tanioka [26] NR; NR; 0.59
Wagner [27]*# NR; NR; 0.59
Alcohol consumption Marcellin 2011 [8]* ≥20 g/day (baseline and
follow-up)
NR; NR; > 0.05
Sola [24]* NR; NR; > 0.05
Depression Lo Re [4] (bipolar/depression) Yes vs. no; OR = 1.00; 0.945
Martín-Santos 2008 [22] (depression and anxiety)#
[Patient Health Questionnaire]
Yes vs. no; MD = −13%; 0.02
Rodis [23] Positive associated with adherence indicators†
Wagner [27]*# Yes vs. no; OR = 0.48; 0.16 to 1.40
Drug use Marcellin 2011 [8]* Yes vs. No; OR = 0.42; 0.23 to 0.77
Sola [24]* NR; NR; > 0.05
Sylvestre [25]*# (regular cocaine/methamphetamin) Yes vs. no; MD = −1%; > 0.05
Yes vs. no; MD = −20%; 0.10
Regular vs. none, rarely, intermittent; MD = −48%; 0.03
Wagner [27]*# Yes vs. no; OR = 1.42; 0.27 to 7.52
Education Marcellin 2011 [8]* (not specified) Low vs. high; OR# = 0.99; 0.80 to 1.23
Wagner [27]*# Any college vs. others; OR = 1.75; 0.60 to 5.11
Employment status Marcellin 2011* [8] Unemployed vs. others; OR# = 1.01; 0.75 to 1.37
Wagner [27]*# Yes vs. no; OR = 0.61; 0.20 to 1.81
Ethnic group Sylvestre [25]*# NR; NR; 0.2
Wagner [27]*# African American vs. others; OR = 0.50; 0.16 to 1.51
Gender Giannelli [21] Male vs. female; OR# = 2.44; 1.41 to 4.22
Marcellin 2011* [8] NR; NR; > 0.05
Sola [24]* NR; NR; > 0.05
Sylvestre [25]*# NR; NR; 0.4
Tanioka [26] Male vs. female; RR = 2.01; 1.07 to 3.79
Wagner [27]*# Male vs. female; OR = 0.85; 0.08 to 8.74
Genotype Marcellin 2011* [8] 3 vs. 1; OR = 1.55; 1.20 to 2.01
Sola [24]* 1 or 4 vs. 2 or 3; OR = 2.6; 1.1 to 6.7
Sylvestre [25]*# 2 or 3 (24 weeks treatment) vs. 1 (48 weeks treatment);
MD = 23%; 0.07
Tanioka [26] 2 vs. 1; RR = 1.84; 1.10 to 3.09
Wagner [27]*# 1 or 4 vs. other; OR = 0.81; 0.25 to 2.66
Haemoglobin level Sola [24]* >14.9 g/dl vs. < 14.9 g/dl; OR = 3.3; 1.4 to 8.1
Tanioka [26] ≥ 14 vs. < 14; RR = 1.50; 0.85 to 2.64
Hepatitis-C virus RNA Marcellin 2011* [8] NR; NR; > 0.05
Sola [24]* NR; NR; > 0.05
Tanioka [26] < 100 vs. ≥100; RR# = 0.49; 0.18 to 1.34
Wagner [27]*# <800,000 vs. other; OR = 1.03; 0.35 to 3.01
HIV co-infection Marcellin 2011* [8] Yes vs. no; OR = 2.52; 1.36 to 4.67
Sola [24]* NR; NR; > 0.05
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group“, ”hepatitis-C virus RNA”, “genotype”, “metavir activ-
ity” and “weight” seem to have no effect on adherence. The
remaining the results differed between studies.
The findings are in accordance with research findings for
other indications. A meta-analysis found a statistically
significant negative effect of depression on adherence in
chronic conditions [28]. This might be attributable to a re-
duced motivation in depressed patients. The question is
therefore, whether the treatment of the psychiatric disorder
can help to increase adherence.
The negative influence of higher doses ribavirin on adher-
ence is probably caused by the higher risk of side effects.
For example, systematic reviews in HIV infected patients
have shown that side effects are a predictor for non-
adherence [29,30]. The assumption that ribavirin intake can
be associated with depression is justified. A low hemoglobin
level is associated with fatigue which can possibly result in
low motivation to take medication. Furthermore, also a low
hemoglobin level and respectively the associated fatigue is a
possible side effect of ribavirin. Therefore, the hemoglobin
level is perhaps also an indicator for side effects.
The two studies that analyzed the influence of an HIV-
co-infection are adjusted for drug use [8,24]. The reason
why this confounder is adjusted for the positive effect of an
HIV-co-infection might be due to the experience in hand-
ling complex treatment regimens in HIV-infected individ-
uals. Furthermore research has indicated, that access to
care is higher in co-infected individuals [31].
Due to the heterogeneity no general conclusions can
be made that can be applied to all settings, countries,
patient groups, etc. This pertains also for the factors that
were highlighted as having an influence, The results
should rather be considered explorative as indications
for factors that can have an influence on adherence in
hepatitis-C infected patients treated with regimes that
contain ribavirin. To be of sufficient significance to make
decisions in clinical practice, the factor/s has/have to be
evaluated in detail for the specific context of the decision.
The main reasons for heterogeneity between studies are the
sample size, the analyses methods, different regimens and
different patient characteristics. Furthermore, all studies re-
vealed methodological flaws. In particular the meas-
urement of influencing factors was mostly unclear.
Also the time point of measurement can have an influ-
ence on adherence. A more recent study shows that at
the first measurement time point younger age and
African American ethnicity were statistically signifi-
cant associated with lower ribavirin adherence. At the
second measurement time point these factors were not
statistically significant anymore, but publicly insured
and employed patients showed a statistically significant
effect in ribavirin adherence.
The measurement of adherence is performed with
various instruments. All types of the applied adherence
measurement instruments are associated with the ten-
dency to overestimate adherence [32]. Most studies use
Table 4 Influence of factors on adherence for factors that were analyzed in more than one study (Continued)
Medication dose
interferon
Marcellin 201* [8] (Peg-Interferon) Positive; NE; 0.003#
Tanioka [26] (million units/kg) < 0.13 vs. ≥ 0.13; RR = 2.42; 1.52 to 3.85
Medication dose
ribavirin
Giannelli [21] Negative; NR; < 0.05
Marcellin 201* [8] Negative; NE; 0.097#
Tanioka [26] (mg/kg) < 11 vs. ≥11; RR# = 1.12; 0.75 to 1.81
Metavir activity Marcellin 2011* [8] NR; NR; > 0.05
Sola [24]* (Score) NR; NR; > 0.05
Psychiatric disorder Lo Re [4] Yes vs. no; OR = 0.99; 0.226
Marcellin 2011 [8]* (baseline and follow up) NR; NR; > 0.05
Sylvestre [25]*# Yes vs. no; MD = to −8%; > 0.05
Wagner [27]*# Yes vs. no; OR = 0.25; 0.08 to 0.76
Treatment experience Lo Re [4] (duration) Decline per 12 weeks; mean = 0.001
Marcellin 2011 [8]* (intended duration) Negative; NE; <0.001#
Tanioka [26] Retreatment vs. naive; RR = 1.86; 1.15 to 3.01
Weight Marcellin 2011 [8]* NR; NR; > 0.05
Sola [24]* NR; NR; > 0.05
Tanioka [26] (kg/BMI) ≥ 60 vs. < 60; RR = 1.09; 0.63 to 1.89
NR; RR# = 1.11; 0.73 to 1.69
NE: not reported and not estimable (e.g. continuous variable); NR: not reported; OR: odds ratio; RR: relative risk; *Analysis based on combined adherence rates for
interferon and ribavirin; #univariate; †wording according to publication.
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self-reports. In particular for self-reporting instruments
a higher estimation of intake rather than the true adher-
ence rate has been shown [32]. Indeed pill counts and
prescription refill are a more objective adherence mea-
sures but also these measurement methods imply the
tendency to overestimate adherence (e.g. trashing tablets).
In none of the included studies timing adherence was
assessed. Thus, for example compensating one missing
ribavirin tabled by double taking on another day would not
have been revealed. However, for a more detailed and pre-
cise assessment usually additional effort is necessary which
is often not feasible in clinical practice.
To have a substantial virologic response, patients have to
reach a certain adherence level. Taking this into account,
the proportion of patients reaching this cut-off value should
be chosen as the operationalization of adherence, instead of
the mean of the entire trial population, as the overall mean
does not allow for a clinically significant estimation of how
many patients can reach the required adherence. To our
knowledge, a precise lower bound of required adherence
(dose and timing) for an adequate suppression of RNA rep-
lication has not yet been proven [7]. Thus, the cut-off
values used in the studies are not proven. It has to be taken
into account that also the variation between patients and
regimens should be analyzed in detail in this context be-
cause the needed adherence to reach a substantial virologic
response probably depends on patient characteristics and/
or the regimen. Furthermore, prior research has shown that
a categorization of variables can result in different pre-
dictors in prognostic models and in poor performance
of the model [33]. However, the mean adherence is
only used as operationalization for adherence in two
studies [4,23]. Apart from this, it is unlikely that adher-
ence is influenced by only one factor but it is rather a
multifactorial problem [9].
The different adherence operationalization and measure-
ments are furthermore a limitation for the comparability of
results and probably one reason for different results regard-
ing the statistical significance and effect direction between
studies. But also the influencing factors differ regarding
operationalization and measurement. For example in all
studies age is operationalized in two categories or continu-
ously. However, studies on other indications have shown
that adherence presents a concave shape i.e. adherence is
highest in the middle age and declines with younger or
older age [34]. Such information is lost (no statistically sig-
nificant results) if e.g. only two categories are used or
age is treated as a continuous variable. The effect of
different categorizations for the same influencing fac-
tor on the results is analyzed in none of the included
studies (sensitivity analysis).
Another comparability limiting point is that the ana-
lyses are adjusted for different factors. Especially the
unadjusted analysis should be interpreted with caution
because confounders or effect modifiers are not accounted
for. But also the multivariate analyses are adjusted for dif-
ferent factors and consequently the comparability is limited.
Although, it was sought to consider confounding in the evi-
dence synthesis, i.e. to identify factors that are independ-
ently associated with adherence, a risk of bias in the results
cannot be excluded.
In two studies, variables that do not contribute to the
explanation of the variance of adherence were not elimi-
nated from the analysis. Consequently the probability of
statistically non-significant results due to inter-correlation
might be raised [25,35]. In the other multivariate analyses
indeed the model is fitted by eliminating variables without
a statistically significant influence on adherence. However,
in none of the multivariate analysis the inter-correlations
(e.g. drug use and alcohol use) between influencing factors
were analyzed. Thus, variables that measure basically the
same phenomena (e.g. mental illness) probably show no
influence in the analysis, because most of the variance in
adherence is explained by one factor (e.g. drug use) leav-
ing little potential for explaining additional variance in ad-
herence by adding the other factor (e.g. alcohol use). The
actual influencing factor or underlying phenomena can
therefore be concealed. In addition some factors that have
shown an influence in other conditions like copayments
and other barriers to access to care were not analyzed in
any of the included studies [36].
The observed high adherence rates in some studies sug-
gest a “ceiling effect”. A high overall adherence level implies
that adherence differences become marginal. Probably the
high adherence is due to the fact that patients participating
in studies are often more adherent than those patients, who
refuse study participation [37]. Furthermore, it can be
presumed that access to medication is ensured for study
participants. The high baseline adherence implies that a
large sample size is needed to show statistical significance
of the results. However, most studies were small and thus
probably underpowered.
The presented systematic review has some limitations.
Firstly, missing relevant literature published in other lan-
guages could not be excluded because we included only
English and German literature [38]. Secondly, we did
not evaluate the quality of registry data in register based
studies. The extent of this source of bias is therefore un-
known. Thirdly, we did not evaluate the risk of bias for
each individual factor, because in most studies for none
of the factors the measurement was described in detail
and consequently all factors would have had to be rated
with unclear risk of bias. But an unclear risk of bias was
judged differently depending on the factor in the evi-
dence synthesis (e.g. age vs. social support).
In this systematic review only implementation adherence
to antiretroviral hepatitis-C therapy was considered be-
cause, persistence and implementation adherence should
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been analyzed separately [15]. It could be hypothesized that
early implementation non-adherence is associated with dis-
continuation. However, in a study that analyzed many vari-
ous potential influencing factors only younger age showed
an influence on discontinuation and also on ribavirin
implementation adherence. Another study showed no sta-
tistically significant association between adherence and can-
nabis users, but cannabis users were statistically significant
more likely to continuing treatment [25]. Also other studies
indicate that the factors influencing implementation ad-
herence and discontinuation differ. Thus, this systematic
review indicates an association between depression and
adherence [39]. Again, a study on the influence of depres-
sion on discontinuation in intravenous drug users found
not statistically significant association. Another study
showed a statistically non-significant influence of drug
addiction and a non-significant effect of psychiatric de-
terioration on discontinuation [40]. Also these results
were contrary to the presented results for implementation
adherence.
In clinical practice the factors can be an indication for
non-adherence, especially if various factors pertain in one
patient. Due to the explorative nature of our analysis, ad-
herence influencing factors in hepatitis-C infected patients
receiving combination therapy with ribavirin should further
be investigated to get deeper insights into the reasons for
non-adherence. Detailed knowledge of adherence influen-
cing factors would facilitate the identification of patients at
risk for non-adherence e.g. the development of screening
tools for non-adherence. The knowledge of adherence in-
fluencing factors can also contribute to the development of
tailored, multifactorial adherence enhancing interventions.
Conclusion
There are some factors that seem to show an influence on
adherence. However, due to the heterogeneity (e.g. patient
characteristics, regimes, settings, countries) no general con-
clusions can be made. The results should rather be consid-
ered as indications for factors that can have an influence on
adherence in hepatitis-C infected patients taking regimes
that containing ribavirin.
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